Aldeyra Therapeutics reports positive NS2 clinical trial results

Aldeyra Therapeutics Inc. has reported that its Phase 2a clinical trial of topical ocular NS2 has shown positive results.

Aldeyra is a biotechnological company that develops medicines for the treatment of aldehyde-related diseases. Its Phase 2a trial of topical ocular NS2 is a randomized, parallel-group, single-center, double-masked, vehicle-controlled clinical trial designed to reduce ocular itching and tearing in subjects who have contracted allergic conjunctivitis.

The data from Aldeyra’s NS2 clinical trials showed that patients with allergic conjunctivitis showed a significant improvement in the reduction of ocular itching and tearing compared to the patients administered with the vehicle during the study.

It is a common thought that aldehydes are directly related to the inflammatory conditions associated with allergic conjunctivitis, and also to other ocular and non-ocular inflammations. The NS2 molecule is an aldehyde trap that has been tested in a conjunctival allergen provocation test (CAPT) form of allergic conjunctivitis.

The Phase 2a trials for NS2 consisted on 100 healthy men and women who have a history of at least two years of contracting allergic conjunctivitis due to grass, tree or ragweed pollen. The patients were then put into two groups, one receiving NS2 while the other received the vehicle.